Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells

International Journal of Molecular Medicine

Volumn 24, Issue 1, 2009, Pages 45-50

  Lee, Eun Mee ^a   Shin, Sangsu ^a   Cha, Hwa Jun ^a   Yoon, Youngmin ^a   Bae, Seunghee ^a   Jung, Jin Hyuk ^a   Lee, Sun Mi ^c   Lee, Su Jae ^d   Park, In Chul ^e   Jin, Young Woo ^e   An, Sungkwan ^a,b  

^a Konkuk University   (South Korea)

^b LIFEnGENE Inc   (South Korea)

^c Hanyang University   (South Korea)

^d Korea Institute of Radiation and Medical Science   (South Korea)

^e Korea Hydro & Nuclear Power Co   (South Korea)

Author keywords

A549 cells; Human non small cell lung cancer; MicroRNA; Suberoylanilide hydroxamic acid

Indexed keywords

MICRORNA; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN; CONTROLLED STUDY; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RNA ANALYSIS; RNA GENE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MICRORNAS; SMALL CELL LUNG CARCINOMA;

EID: 67649518730     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000204     Document Type: Article

References (30)

1. Cinatl J Jr, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW and Kornhuber B: Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 7: 766-773, 1996.
2. Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y and Jones DR: Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the akt pathway. J Biol Chem 278: 18980-18989, 2003.
3. Verdin E, Dequiedt F and Kasler HG: Class II histone deacetylases: versatile regulators. Trends Genet 19: 286-293, 2003.
4. Marks PA, Richon VM, Miller T and Kelly WK: Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168, 2004.
5. M6cLaughlin F and La Thangue NB: Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 68: 1139-1144, 2004.
6. Acharya MR, Sparreboom A, Venitz J and Figg WD: Rational development of histone deacetylase inhibitors as anticancer agents. Mol Pharmacol 68: 917-932, 2005.
7. Kelly WK and Marks PA: Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150-157, 2005.
8. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006.
9. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006.
10. Dokmanovic M, Clarke C and Marks PA: Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5: 981-989, 2007.
11. Rasheed WK, Johnstone RW and Prince HM: Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 16: 659-678, 2007.
12. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
13. Kelly WK, Richon WM, O'Connor O, et al: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578-3588, 2003.
14. Kelly WK, Richon VM, O' Connor OA, et al: Phase I study of the oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), in patients with advanced cancer. J Clin Oncol 23: 3923-3931, 2005.
15. Denlinger CE, Rundall BK and Jones DR: Proteasome inhibition sensitizes non-small lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 128: 740-748, 2004.
16. Kuljaca S, Liu T, Tee AE, Haber M, Norris MD, Dwarte T and Marshall GM: Enhancing the anti-angiogenic action of histone deacetylase inhibitors. Mol Cancer 6: 68, 2007.
17. Pillai RS, Bhattacharyya SN and Filipowicz W: Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17: 118-126, 2007.
18. Luthra R, Singh RR, Luthra MG, et al: MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene 27: 6667-6678, 2008.
19. Raver-Shapira N, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z and Oren M: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731-743, 2007.
20. Ambros V and Chen X: The regulation of genes and genomes by small RNAs. Development 134: 1635-1641, 2007.
21. Rana TM: Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 8: 23-36, 2007.
22. Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
23. Eder M and Scherr M: MicroRNA and lung cancer. N Engl J Med 352: 2446-2448, 2005.
24. Nana-Sinkam SP and Geraci MW: MicroRNA in lung cancer. J Thorac Oncol 1: 929-931, 2006.
25. Kwon HJ, Kim MS, Kim MJ, Nakajima H and Kim KW: Histone deacetylase inhibitor fk228 inhibits tumor angiogenesis. Int J Cancer 97: 290-296, 2002.
26. Deroanne CF, Bonjean K, Servotte S, et al: Histone deacetylases inhibitors as antiangiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-436, 2002.
27. Michaelis M, Suhan T, Cinatl J, Driever PH and Cinatl J Jr: Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol 25: 1795-1799, 2004.
28. Subramanian C, Opipari Jr AW, Bian X, Castle VP and Kwok RP: Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 4842-4847, 2005.
29. Cohen HY, Lavu S, Bitterman KJ, et al: Acetylation of the c terminus of ku70 by cbp and pcaf controls bax-mediated apoptosis. Mol Cell 13: 627-638, 2004.
30. John B, Enright AJ, Aravin A, Tuschi T, Sander C and Marks D: Human microRNA targets. PLoS Biol 2: E363, 2004.